Lewy body dementia pill missed main trial goal; maker cites low drug levels

The full placebo-controlled results of a trial of neflamapimod, an experimental pill for dementia with Lewy bodies, have been published in the journal Alzheimer’s Research & Therapy, the drug’s maker CervoMed announced on October 29, 2026.¹ The paper confirms what the company had already said in earlier announcements: the pill did not beat placebo (a dummy pill) on the trial’s main measure across everyone who took part.¹ CervoMed argues that the capsules used delivered too little drug, and it points to subgroups and drug-level analyses that it says look more promising.¹

What happened

The trial, called RewinD-LB, enrolled 159 people and compared neflamapimod, taken as 40 mg three times a day, with a dummy pill.¹ Participants had very mild or mild dementia due to Lewy bodies, and the placebo-controlled part lasted 16 weeks.² It was a Phase 2b trial, a mid-sized test meant to check whether a drug shows enough benefit to justify a larger, final-stage study.

The main measure was change on the Clinical Dementia Rating Sum of Boxes (CDR-SB), a standard score doctors use to rate memory, thinking and everyday functioning, where higher numbers mean worse dementia.² According to the company’s summary of the paper, neflamapimod “did not confirm” the results of its earlier, smaller trial on that measure in the full group of participants.¹

The first author of the paper is John-Paul Taylor, a professor of translational dementia research at Newcastle University and chief investigator of the trial in the United Kingdom.¹ The same announcement reported a second paper, in the journal Cells, with lab and clinical data suggesting the drug blocks signals from IL-1β, an inflammation messenger, which the company links to nerve damage in the disease.¹

The evidence so far

Beyond the main result, the company highlighted several findings from the paper:

• Brain scans. In a smaller group who had MRI scans, people on neflamapimod showed a statistically significant increase in the volume of the right basal forebrain, a small area at the base of the brain, compared with placebo.¹ The company said this fits with an effect on the disease process.¹
• People without Alzheimer’s changes. On the dementia rating, the drug looked better in people who did not appear to also have Alzheimer’s-type brain changes, judged by a blood marker called pTau181.¹ In one such group the difference from placebo was 0.51 points in the drug’s favor, but the statistical range ran from 1.16 points better to 0.13 points worse, meaning the result could not rule out no effect.¹
• Drug levels. People whose blood levels of the drug were above the trial’s middle value (3.64 ng/mL) showed effects on the dementia rating similar to those seen in the earlier trial; people below it did not.¹
• Safety. Stopping treatment because of side effects happened in 2.5% of people on neflamapimod and 1.3% on placebo.¹ Only one of those cases was judged possibly drug-related: temporarily raised liver enzymes in a person with an existing liver condition, which went back to normal after the drug was stopped.¹

What it does not show yet

The trial’s main pre-planned test was not met. The subgroup and drug-level findings are the kind of after-the-fact analyses that can point to ideas worth testing but cannot confirm that a drug helps. A July 2026 company filing, as summarized by the financial site Stock Titan, said explicitly that the trial did not replicate the earlier result and that the supporting subgroup findings are exploratory.³

Drug-level comparisons carry a particular risk: people who end up with higher blood levels may differ from others in ways that also affect how their disease progresses. The paper does not, by itself, separate those possibilities.

The company’s explanation for the miss is that the capsules used in the placebo-controlled part produced lower-than-intended drug exposure.¹ In December 2025 CervoMed said this lower absorption was later traced to the age of the capsules.⁴ In a follow-on phase where everyone got the drug, some participants received a new batch of capsules, and the company has reported better dementia-rating results in that group than in people who stayed on the old batch.⁴ Those extension results come from comparisons the company built after the fact, not from a fresh placebo-controlled trial, and the full extension data are due in a separate paper.¹

Who is behind it

CervoMed, a Boston company listed on the Nasdaq exchange, develops the drug.¹ Before the company took that name, the drug was developed by EIP Pharma, whose chief executive John Alam now leads CervoMed.⁵¹ The trial itself was paid for by a $21 million grant from the US National Institute on Aging, part of the National Institutes of Health, and ran at 43 sites in the United States, the United Kingdom and the Netherlands.²

Both people quoted in the announcement have a stake in the program. Taylor led the UK arm of the trial.¹ He said the placebo-controlled data, together with the earlier trial, provide “encouraging evidence that neflamapimod may be an effective treatment for DLB and that further clinical evaluation is warranted.”¹ Alam said the company believes the clinical, blood-marker and scan findings support further development, especially in patients without Alzheimer’s co-pathology.¹

The company’s finances matter for what happens next. As of March 31, 2026, CervoMed reported about $7.9 million in cash and about $5.0 million in short-term investments, and a final-stage trial depends on getting funding or a partner, according to the filing summary.³

How it fits the field

Dementia with Lewy bodies causes problems with attention, thinking and walking, and a patient group describes it as the second most common dementia.⁵ James Galvin, a co-principal investigator and board member of the Lewy Body Dementia Association, has said there are no approved therapies for the disease and that standard care does not change its progression.⁵

Neflamapimod received Fast Track status from the US Food and Drug Administration in 2019, a label that can speed up review, and an earlier, smaller trial called AscenD-LB reported positive results in 2020 that were published in 2022.⁵ RewinD-LB was designed to confirm those findings, and only enrolled people whose blood test suggested they did not also have Alzheimer’s-type changes.²

Other drugs are also being tested. In 2025 the Lewy Body Dementia Association noted that three mid-stage trials in the disease had recently reported, including neflamapimod and a drug called CT1812, and said none of these drugs are likely to be available for at least a few more years, if at all.⁶

What to watch next

• A new dose. Alam said the results support a 100 mg twice-daily dose using a new tablet, which the company projects would reach its target blood level in more than 90% of patients.¹ That differs from July 2026, when the company described a planned 50 mg three-times-daily dose.³
• A final-stage trial. In December 2025 CervoMed said it was preparing to start a final-stage trial in the second half of 2026.⁴ By July 2026 that plan was described as dependent on funding or a strategic partner.³
• A small safety study. A separate 26-person study of 80 mg twice daily, with no placebo group, is listed as completed, with results not yet posted on the US trial registry.⁷ The company said it met its safety and drug-level goals.³
• The extension paper. Full results from the 32-week phase in which everyone received the drug are expected in a separate publication.¹ Of the 159 people randomized, 149 entered that phase.⁸